IL2 and cancer: Pro-inflammatory payloads increase NK- and T-lymphocyte killing capability, but some of them (e.g., IL-2) enhance immunosuppressive properties of Tregs (regulatory T cells), mostly an unwanted effect during cancer treatment [48].